Johnson & Johnson
JNJ
$243.04
-0.44%
Johnson & Johnson is a global healthcare firm operating in the drug manufacturing and medical technology sectors. It is the world's largest and most diverse healthcare company, with a restructured focus on innovative medicine in immunology, oncology, and neurology following the divestment of its consumer business.…
JNJ
Johnson & Johnson
$243.04
Related headlines
Investment Opinion: Should I buy JNJ Today?
Based on a synthesis of strong fundamentals, a healthy balance sheet, positive growth catalysts from recent drug approvals, and a reasonable valuation as indicated by a low PEG ratio, the objective assessment leans positive. However, the stock's proximity to its 52-week high and mixed analyst sentiment warrant caution. The Synthesized Analyst Rating for JNJ is a Hold. The current price already reflects much of the near-term optimism, making it more suitable for existing shareholders or those seeking a defensive, dividend-paying healthcare stock rather than a clear-cut buying opportunity for new capital.
Sign up to view all
JNJ 12-Month Price Forecast
JNJ is a high-quality company with strong financials and positive catalysts, but its recent significant price appreciation to near 52-week highs limits the near-term margin of safety. The risk/reward appears balanced at current levels.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $315.95 and implied upside of +30.0% versus the current price.
Average Target
$315.95
7 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
7
covering this stock
Price Range
$194 - $316
Analyst target range
Wall Street analyst coverage for Johnson & Johnson is active, with recent ratings from major firms including 'Buy' from Citigroup and HSBC, 'Overweight' from Morgan Stanley, and 'Neutral' or 'Equal Weight' from JP Morgan and Barclays. Specific consensus price targets and a detailed ratings distribution are not provided in the data. The available information indicates a generally positive but mixed view, with several firms maintaining bullish stances while others recommend holding the stock.
Bulls vs Bears: JNJ Investment Factors
Johnson & Johnson demonstrates strong fundamental performance with robust revenue growth, profitability, and a solid balance sheet, supported by recent FDA approvals. However, the stock trades near its 52-week high, faces competitive pressures, and carries a premium valuation. The overall picture is positive but suggests near-term upside may be limited.
Bullish
- Strong Revenue Growth and Profitability: Q4 revenue grew 9.1% YoY, with a robust trailing net margin of 28.5%.
- Solid Financial Health and Cash Flow: Strong free cash flow of $19.7B TTM and a moderate debt-to-equity ratio of 0.59.
- Recent Key FDA Approvals: FDA nod for psoriasis pill Icotyde and combo therapy for multiple myeloma provide growth catalysts.
- Strong Relative Stock Performance: Stock up 31.4% over 6 months, significantly outperforming the S&P 500.
Bearish
- Trading Near 52-Week High: Current price is 97% of 52-week high, suggesting limited near-term upside.
- Mixed Analyst Sentiment: Analyst ratings are mixed, with some firms neutral or equal-weight.
- Potential Portfolio Restructuring Risks: News of a potential sale of DePuy Synthes introduces execution and integration risks.
- Intense Competition in Key Markets: Strong competition from AbbVie's Skyrizi in immunology and other drugmakers.
JNJ Technical Analysis
The stock has demonstrated a strong and sustained uptrend over the past six months, rising 31.43% from an October 2025 low near $186 to a current price of $244.44. This performance significantly outpaces the broader market, as evidenced by a 34.25 relative strength over the same period. In the short term, the stock has shown resilience, gaining 18.12% over the last three months despite a slight 1.61% pullback over the past month. The current price of $244.44 sits near the upper end of its 52-week range of $141.50 to $251.71, indicating the stock is trading at elevated levels. The price is approximately 97% of its 52-week high, suggesting limited immediate upside based on recent historical ranges, though momentum indicators like the positive relative strength figures show persistent buying pressure.
Beta
0.33
0.33x market volatility
Max Drawdown
-12.7%
Largest decline past year
52-Week Range
$142-$252
Price range past year
Annual Return
+56.4%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | -1.5% | -3.6% |
| 3m | +17.2% | -4.0% |
| 6m | +28.8% | -2.0% |
| 1y | +56.4% | +16.2% |
| ytd | +17.2% | -3.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue growth has been positive, with Q4 2025 revenue of $24.56 billion representing a 9.08% year-over-year increase. Profitability is robust, with a trailing net margin of 28.46% and a quarterly operating margin of 21.95% in Q4 2025, though this marks a sequential decline from the exceptionally high gross margin of 86.37% reported for that quarter, which may include one-time items. The company maintains a solid financial position with a debt-to-equity ratio of 0.59, indicating moderate leverage, and generates substantial cash flow, with trailing twelve-month free cash flow of $19.70 billion. Operational efficiency is strong, as reflected in a high return on equity of 32.87% and a return on assets of 8.68%, demonstrating effective use of shareholder capital and company assets.
Quarterly Revenue
$24.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given the company's consistent profitability with a positive net income, the primary valuation metric is the price-to-earnings (P/E) ratio. Johnson & Johnson trades at a trailing P/E of 18.81 and a forward P/E of 19.45, which suggests the market is pricing in stable, moderate growth expectations. The PEG ratio of 0.21, based on trailing metrics, indicates the stock may be undervalued relative to its earnings growth rate, though this figure should be interpreted with caution as it may not reflect forward-looking consensus. Peer comparison data for industry averages is not available in the provided inputs, so a relative valuation assessment cannot be made.
PE
18.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1502x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.3x
Enterprise Value Multiple
Investment Risk Disclosure
Johnson & Johnson's primary risks stem from its competitive environment and execution challenges. The healthcare sector is highly competitive, with recent news highlighting strong competition from AbbVie's Skyrizi in immunology, which could pressure market share and pricing power for JNJ's key drugs. Regulatory and clinical trial risks are ever-present, though recent FDA approvals for Icotyde and a multiple myeloma combo therapy are positive. Operational risks include the potential mega-sale of its DePuy Synthes orthopedics unit, which, while strategically aimed at focusing on higher-growth areas, introduces significant execution and integration risks that could disrupt operations and financial performance. Furthermore, the stock's technical position is a risk, as it trades at 97% of its 52-week high after a 31% six-month rally, increasing vulnerability to a market pullback or profit-taking, despite its low beta of 0.33 indicating less volatility than the market.
FAQ
Key risks include competitive pressures, particularly in immunology from drugs like AbbVie's Skyrizi. Execution risk surrounds the potential sale of its DePuy Synthes orthopedics business. Regulatory and clinical trial setbacks for its pipeline are always a concern. Finally, stock-specific risk includes a potential pullback as the price is near its 52-week high after a significant rally, increasing vulnerability to profit-taking.
The 12-month outlook is for moderate growth with a base case target range of $240-$260, representing a slight increase from the current ~$244 price. The bull case (30% probability) sees a breakout to $260-$280 on successful drug launches, while the bear case (15% probability) envisions a pullback to $200-$230 on competitive or market pressures. The consensus view is neutral, expecting the stock to consolidate recent gains.
JNJ's valuation sends mixed signals. Its forward P/E of 19.45 is reasonable for a stable healthcare giant, and its PEG ratio of 0.21 suggests it is undervalued relative to its growth rate. However, its price-to-book ratio of 6.18 is elevated. Overall, the stock appears fairly valued to slightly overvalued based on its current price near the top of its historical range, balancing strong fundamentals against a premium price.
JNJ is a high-quality stock, but its attractiveness as a new buy is muted at current levels. The company has strong fundamentals, including a 28.5% net margin and $19.7B in annual free cash flow. However, the stock has rallied 31% in six months and trades at 97% of its 52-week high, suggesting limited near-term upside. It is better suited for existing shareholders or those waiting for a pullback.
JNJ is primarily suitable for long-term investment. Its status as a Dividend King with 63 years of dividend growth, AAA credit rating, and leadership in the essential healthcare sector provides stability and income for a long-term portfolio. The stock's low beta (0.33) also makes it a defensive holding. For short-term traders, the limited technical upside and high valuation multiples present less compelling opportunities.